Stephanie Tung, MBBChBAO, MSc
Physician in Medicine, Division of Newborn Medicine
Instructor of Pediatrics, Harvard Medical School
Image
Stephanie Tung, MBBChBAO, MSc
Physician in Medicine, Division of Newborn Medicine
Instructor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Undergraduate School
University of Toronto
2010
Toronto, Ontario
Canada
Graduate School
University of Toronto
2013
Toronto, Ontario
Canada
Medical School
Royal College of Surgeons in Ireland
2017
Dublin
Ireland
Internship
Pediatrics
Johns Hopkins Pediatric Residency Program
2018
Baltimore
MD
Residency
Pediatrics
Johns Hopkins Pediatric Residency Program
2020
Baltimore
MD
Fellowship
Neonatal-Perinatal Medicine
Harvard Neonatal Perinatal Medicine Fellowship
2023
Boston
MA
Certifications
American Board of Pediatrics (General)
Professional History
Dr. Stephanie Tung is an Attending Physician in Medicine in the Division of Newborn Medicine at Boston Children’s Hospital. She is also an Instructor of Pediatrics at Harvard Medical School. Dr. Tung is a graduate of the University of Toronto and received her medical degree from the Royal College of Surgeons in Ireland. She completed her training in pediatrics at the Johns Hopkins Pediatric Residency Program in Baltimore and her neonatology training in the Harvard Neonatal-Perinatal Medicine Fellowship program.
Dr. Tung's research focuses on evaluating the long-term immunologic implications of bronchopulmonary dysplasia.
Publications
Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer. View Abstract
Harnessing the therapeutic potential of the stem cell secretome in neonatal diseases. View Abstract
Fetal Disseminated Malignant Rhabdoid Tumor. View Abstract
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. View Abstract
PPARa and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. View Abstract
PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. View Abstract
A role for Danazol in chronic lymphocytic leukemia. View Abstract
Locations